Werewolf reports Q2 2026 financial results, cash down to $22M
Werewolf Therapeutics reported Q2 2026 financial results noting a decrease in cash position to $22.0 million, following completion of a $21.0 million collaboration revenue transaction with Jazz Pharmaceuticals.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day